TNKS or TNKS2 overexpression, either at the mRNA or protein level, has been described in numerous malignancies, including gastric cancer (Gao et al., 2011, Matsutani et al., 2001), breast cancer (Gelmini et al., 2004), bladder cancer (Gelmini et al., 2007), astrocytoma (Tang et al., 2012), glioblastoma (Shervington et al., 2007), pancreatic cancer (Zhao et al., 2009), lung cancer (Busch et al., 2013), and colon cancer (Gelmini et al., 2006, Shebzukhov et al., 2008). Here, TNKS is linked to urinary bladder cancer.